Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133492) titled 'Evaluation of the efficacy and safety of omalizumab in the treatment of pregnant patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study' on Sept. 28.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Affiliated Hospital of Chongqing Medical University
Condition:
Chronic spontaneous urticaria
Intervention:
Placebo group:Antihistamine [loratadine (10mg qd)] and placebo [using sterile water for injection] were administered.
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-10-08
Target Sample Size: Pla...